Apimeds Pharmaceuticals US
APUS
7 hedge funds and large institutions have $384K invested in Apimeds Pharmaceuticals US in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
0.07% less ownership
Funds ownership: 0.36% → 0.28% (-0.07%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
52% less capital invested
Capital invested by funds: $803K → $384K (-$419K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$21.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$44K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$18.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$6.73K |
APUS Hedge Fund Activity: Q2 2026 in Review
7 of the 8,320 institutional investors tracked by Wall St. Rank reported a position in Apimeds Pharmaceuticals US (APUS) for Q2 2026, worth a combined $384K — down 52% from $803K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new APUS positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $21.8K. The largest seller was Vanguard Capital Management, cutting an estimated $44K.
- 7 institutional investors held Apimeds Pharmaceuticals US (APUS) as of Q2 2026, up from 6 in Q1 2026.
- Funds reported $384K of Apimeds Pharmaceuticals US stock for Q2 2026, down 52% quarter-over-quarter.
- 2 funds opened new Apimeds Pharmaceuticals US positions in Q2 2026 and 1 closed out, a net change of +1 holder.
- The largest Apimeds Pharmaceuticals US buyer in Q2 2026 was Jane Street, an estimated $21.8K added.
- The largest Apimeds Pharmaceuticals US seller in Q2 2026 was Vanguard Capital Management, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2026.